Section 159: Microbiome Sequencing and Personalized Probiotics in CBS/PSP

📖 Wiki Page

therapeutic2513 wordssynced 2026-04-02

Section 159: Microbiome Sequencing and Personalized Probiotics in CBS/PSP

Introduction

...

Section 159: Microbiome Sequencing and Personalized Probiotics in CBS/PSP

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 159: Microbiome Sequencing and Personalized Probiotics in CBS/PSP</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>16S rRNA Sequencing</td>
</tr>
<tr>
<td class="label">Target</td>
<td>V1-V9 variable regions</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>$150-400</td>
</tr>
<tr>
<td class="label">Turnaround</td>
<td>2-4 weeks</td>
</tr>
<tr>
<td class="label">Resolution</td>
<td>Genus/species level</td>
</tr>
<tr>
<td class="label">Limitations</td>
<td>Cannot distinguish strains</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Shotgun Metagenomics</td>
</tr>
<tr>
<td class="label">Target</td>
<td>All microbial DNA</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>$400-1000</td>
</tr>
<tr>
<td class="label">Turnaround</td>
<td>3-6 weeks</td>
</tr>
<tr>
<td class="label">Resolution</td>
<td>Strain level</td>
</tr>
<tr>
<td class="label">Limitations</td>
<td>Complex data analysis</td>
</tr>
<tr>
<td class="label">Service</td>
<td>Method</td>
</tr>
<tr>
<td class="label">Thryve</td>
<td>16S + metaproteomics</td>
</tr>
<tr>
<td class="label">Viome</td>
<td>Metatranscriptomics</td>
</tr>
<tr>
<td class="label">Microbiome Health</td>
<td>16S + metabolomics</td>
</tr>
<tr>
<td class="label">Zoe</td>
<td>Metagenomics + ML</td>
</tr>
<tr>
<td class="label">Service</td>
<td>Method</td>
</tr>
<tr>
<td class="label">Genova Diagnostics</td>
<td>16S + culture</td>
</tr>
<tr>
<td class="label">Doctor's Data</td>
<td>16S + SCFA</td>
</tr>
<tr>
<td class="label">MapMyMicrobiome</td>
<td>Shotgun</td>
</tr>
<tr>
<td class="label">Cosmos ID</td>
<td>qPCR + sequencing</td>
</tr>
<tr>
<td class="label">Metric</td>
<td>Healthy Range</td>
</tr>
<tr>
<td class="label">Shannon Index</td>
<td>3.5-5.0</td>
</tr>
<tr>
<td class="label">Observed ASVs</td>
<td>150-400</td>
</tr>
<tr>
<td class="label">Chao1</td>
<td>200-500</td>
</tr>
<tr>
<td class="label">Taxonomic Group</td>
<td>Healthy Level</td>
</tr>
<tr>
<td class="label">Akkermansia muciniphila</td>
<td>>5% of microbiota</td>
</tr>
<tr>
<td class="label">Bifidobacterium</td>
<td>2-10%</td>
</tr>
<tr>
<td class="label">Lactobacillus</td>
<td>1-5%</td>
</tr>
<tr>
<td class="label">Faecalibacterium</td>
<td>5-15%</td>
</tr>
<tr>
<td class="label">Prevotella</td>
<td>10-30%</td>
</tr>
<tr>
<td class="label">Roseburia</td>
<td>2-8%</td>
</tr>
<tr>
<td class="label">Strain</td>
<td>Evidence Level</td>
</tr>
<tr>
<td class="label">L. plantarum 299v</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">L. reuteri DSM 17938</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">L. rhamnosus GG</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">L. bulgaricus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">L. acidophilus NCFM</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Strain</td>
<td>Evidence Level</td>
</tr>
<tr>
<td class="label">B. longum 1714</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">B. breve 1205</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">B. infantis 35624</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">B. lactis HN019</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">B. bifidum MIMBb75</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Optimal dose</td>
<td>10^8 - 10^10 viable cells</td>
</tr>
<tr>
<td class="label">Form</td>
<td>Live or pasteurized (pasteurized still effective)</td>
</tr>
<tr>
<td class="label">Evidence</td>
<td>Strong for barrier integrity, metabolic health</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Excellent safety profile</td>
</tr>
<tr>
<td class="label">Note</td>
<td>Requires prebiotic substrate (polyphenols)</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Minimum 8-12 weeks for assessment</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>With meals (30 min before or with food)</td>
</tr>
<tr>
<td class="label">Storage</td>
<td>Refrigerate; most require cool storage</td>
</tr>
<tr>
<td class="label">Loading dose</td>
<td>First 2 weeks: double dose</td>
</tr>
<tr>
<td class="label">Maintenance</td>
<td>Standard dose thereafter</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Probiotic Interaction</td>
</tr>
<tr>
<td class="label">Levodopa/Carbidopa</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">Antidepressants (SSRIs)</td>
<td>May enhance effect</td>
</tr>
<tr>
<td class="label">Antibiotics</td>
<td>Probiotics contraindicated</td>
</tr>
<tr>
<td class="label">Proton pump inhibitors</td>
<td>Probiotics still effective</td>
</tr>
<tr>
<td class="label">Anticholinergics</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Study</td>
</tr>
<tr>
<td class="label">Reduced alpha diversity in PSP</td>
<td>Barone et al., 2020</td>
</tr>
<tr>
<td class="label">Decreased Faecalibacterium</td>
<td>Houser et al., 2022</td>
</tr>
<tr>
<td class="label">Altered Firmicutes/Bacteroidetes</td>
<td>Tan et al., 2021</td>
</tr>
<tr>
<td class="label">Increased pro-inflammatory taxa</td>
<td>Bedarf et al., 2017</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Study</td>
</tr>
<tr>
<td class="label">Probiotics improve cognition in AD</td>
<td>Akbari et al., 2016</td>
</tr>
<tr>
<td class="label">L. plantarum reduces inflammation</td>
<td>Moya-Perez et al., 2017</td>
</tr>
<tr>
<td class="label">B. longum reduces stress response</td>
<td>Allen et al., 2016</td>
</tr>
<tr>
<td class="label">Multi-strain probiotic in PD</td>
<td>Tortelli et al., 2020</td>
</tr>
<tr>
<td class="label">Akkermansia improves barrier</td>
<td>Depommier et al., 2019</td>
</tr>
<tr>
<td class="label">Service</td>
<td>Cost Range</td>
</tr>
<tr>
<td class="label">16S sequencing</td>
<td>$150-400</td>
</tr>
<tr>
<td class="label">Shotgun metagenomics</td>
<td>$400-1000</td>
</tr>
<tr>
<td class="label">Metabolomics</td>
<td>$300-800</td>
</tr>
<tr>
<td class="label">Full service (comprehensive)</td>
<td>$500-1500</td>
</tr>
<tr>
<td class="label">Product Type</td>
<td>Monthly Cost</td>
</tr>
<tr>
<td class="label">Consumer probiotics</td>
<td>$20-50</td>
</tr>
<tr>
<td class="label">Professional brands</td>
<td>$30-80</td>
</tr>
<tr>
<td class="label">Custom formulations</td>
<td>$50-150</td>
</tr>
<tr>
<td class="label">Therapeutic dose (medical)</td>
<td>$80-200</td>
</tr>
</table>

The gut microbiome has emerged as a critical modifiable factor in neurodegenerative diseases, including corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). While Section 101 detailed the mechanistic links between gut dysbiosis and tauopathy pathogenesis, and Section 123 covered intervention strategies, this section focuses on the diagnostic and personalized therapeutic approach—microbiome sequencing and targeted probiotic supplementation.

Personalized probiotic recommendations based on individual microbiome profiles represent a paradigm shift from generic supplementation to precision nutrition. By understanding a patient's specific microbial community structure, practitioners can recommend targeted interventions that address identified deficiencies and restore microbial balance. This approach is particularly relevant for CBS/PSP patients, where gut dysfunction may contribute to neuroinflammation and disease progression.

1. Microbiome Testing Methods

1.1 Overview of Sequencing Technologies

Mermaid diagram (expand to render)

1.2 16S rRNA Gene Sequencing

16S rRNA sequencing targets the conserved 16S ribosomal RNA gene found in all bacteria, allowing identification of bacterial communities at genus and sometimes species level[@hamady2009].

Best for:

Initial microbiome screening
Diversity and composition analysis
Comparing to reference populations
Tracking changes over time

1.3 Shotgun Metagenomic Sequencing

Shotgun metagenomics sequences all DNA fragments in a sample, providing strain-level resolution and functional gene profiling[@quince2017].

Best for:

Detailed strain-level analysis
Functional pathway assessment
Antimicrobial resistance gene detection
Research applications

1.4 Complementary Testing Approaches

Metatranscriptomics:

Measures active gene expression
Reveals functional activity (not just presence)
Cost: $500-1500
Useful for understanding active metabolic pathways

Metabolomics:

Profiles microbial metabolites directly
SCFAs, bile acids, neurotransmitters
Cost: $300-800
Validates functional output of microbiome

Clinical Recommendation: For CBS/PSP patients, a combination of 16S sequencing with targeted metabolomics provides the best balance of cost, actionable information, and functional insight.

2. Available Testing Services

2.1 Consumer-Directed Testing

2.2 Clinical-Grade Testing

2.3 Specialized Neuroscience Focus

Several testing services have emerged specifically targeting the gut-brain axis:

Recommended for CBS/PSP:

Thryve Inside — Provides strain-specific probiotic recommendations based on microbiome profile, with formulations targeting neurological health
Viome Brain Health — AI analysis specifically trained on gut-brain connection data
Zoe PREDICT — Personalized nutrition based on gut microbiome and postprandial responses

3. Interpreting Microbiome Results

3.1 Key Metrics for CBS/PSP

Mermaid diagram (expand to render)

3.2 Alpha Diversity

Alpha diversity measures within-sample diversity:

CBS/PSP findings: Studies indicate reduced alpha diversity in PSP patients, correlating with disease severity and motor impairment[@barone2020].

3.3 Taxonomic Markers

Bacterial groups of particular interest in CBS/PSP:

3.4 Functional Indicators

Short-chain fatty acid (SCFA) production:

Butyrate: >10% of total SCFAs (optimal)
Propionate: 10-20%
Acetate: 50-70%

CBS/PSP implication: Reduced butyrate production is commonly observed and correlates with gut barrier dysfunction and systemic inflammation[@houser2022].

4. Personalized Probiotic Recommendations

4.1 Strain-Specific Benefits

Mermaid diagram (expand to render)

4.2 Lactobacillus Species

Key strains for CBS/PSP:

CBS/PSP-specific recommendations:

For reduced diversity: L. plantarum 299v
For mood/cognitive symptoms: L. reuteri
For barrier dysfunction: L. rhamnosus GG

4.3 Bifidobacterium Species

Key strains for CBS/PSP:

CBS/PSP-specific recommendations:

For neuroinflammation: B. infantis 35624
For cognitive/mood: B. longum 1714
For immune support: B. lactis HN019

4.4 Akkermansia muciniphila

A. muciniphila is a mucin-degrading bacterium with particularly strong evidence for gut-brain axis benefits[@depommier2019]:

CBS/PSP relevance:

Restores gut barrier integrity
Reduces endotoxemia
Anti-inflammatory effects
May reduce alpha-synuclein propagation

4.5 Combination Formulations

Recommended combinations for CBS/PSP:

Basic formulation:

L. plantarum 299v — 10 billion CFU
B. longum 1714 — 2 billion CFU
L. rhamnosus GG — 10 billion CFU

Enhanced formulation (添加):

A. muciniphila — 5 billion CFU
B. infantis 35624 — 1 billion CFU
L. reuteri DSM 17938 — 5 billion CFU

Anti-inflammatory formulation:

B. breve 1205 — 10 billion CFU
L. acidophilus NCFM — 10 billion CFU
B. lactis HN019 — 10 billion CFU

5. Clinical Implementation

5.1 Assessment Protocol

Mermaid diagram (expand to render)

5.2 Patient Selection

Ideal candidates for microbiome-guided probiotic therapy:

Confirmed CBS/PSP diagnosis — Tauopathy confirmed

Gut symptoms present — Constipation, bloating, altered bowel habits

Stool sample available — Willing to provide sample

Able to follow protocol — Can take supplements consistently

No significant immunosuppression — Safety considerations

Stable medication regimen — Avoid interactions

Relative contraindications:

Active gastrointestinal infection
Severe immunocompromise
Recent antibiotic exposure (wait 4 weeks)
Active inflammatory bowel disease

5.3 Dosing and Administration

Monitoring parameters:

Bowel habit changes
bloating/gas (expect temporary increase)
Cognitive/mood changes
Inflammatory markers (optional)

5.4 Integration with Existing Treatments

Coordination with standard CBS/PSP therapies:

6. Evidence Base

6.1 Microbiome Alterations in Tauopathies

6.2 Probiotic Evidence in Neurodegeneration

6.3 Specific CBS/PSP Evidence

Direct evidence in CBS/PSP remains limited, with most data extrapolated from:

Parkinson's disease studies (similar alpha-synuclein pathology)
Alzheimer's disease studies (similar tau pathology)
General neurodegeneration studies

Ongoing trials:

NCT06033890: Urolithin A and microbiome modulation in PSP
NCT05864297: Probiotic supplementation in PSP (recruiting)

7. Costs and Practical Considerations

7.1 Testing Costs

7.2 Probiotic Costs

7.3 Total Investment

Estimated annual cost for microbiome-guided probiotic therapy:

Initial testing: $300-1000 (one-time)
Probiotic supplements: $600-2400
Follow-up testing (optional): $300-800
Total: $900-4200/year

8. Decision Framework

Mermaid diagram (expand to render)

8.1 Recommendations by Resource Level

Full protocol (ideal):

Comprehensive microbiome sequencing + metabolomics

Personalized probiotic formulation based on results

Follow-up testing at 3 months

Ongoing adjustment as needed

Limited resources:

Basic 16S screening

Empiric multi-strain probiotic (see Section 123)

Symptom tracking

Consider advanced testing if no response

No resources for testing:

Evidence-based multi-strain probiotic

Prebiotic supplementation (fiber, polyphenols)

Dietary modification (Mediterranean diet)

Monitor and track response

9. Summary and Recommendations

9.1 Key Takeaways

Microbiome testing enables personalized probiotic recommendations — Identifying specific deficiencies allows targeted intervention rather than generic supplementation

16S sequencing provides sufficient resolution for most clinical applications — Cost-effective with actionable results for probiotic selection

Strain-specific effects matter — Generic "probiotic" labels are insufficient; specific strains have documented neurological effects

A. muciniphila appears particularly relevant for CBS/PSP — Barrier integrity and anti-inflammatory effects align with tauopathy mechanisms

Integration with standard care is feasible — No significant interactions with standard CBS/PSP medications

9.2 Clinical Algorithm

Recommended approach for CBS/PSP patients:

Screen — Assess for gut symptoms and willingness for testing

Test — Offer microbiome sequencing when feasible

Interpret — Identify key deficiencies and functional gaps

Prescribe — Personalized multi-strain formulation

Monitor — Track symptoms and consider follow-up testing

Adjust — Modify protocol based on response

9.3 Future Directions

The field of microbiome-guided precision probiotics is rapidly evolving:

Strain-specific databases — Growing evidence for individual strain effects
Machine learning integration — AI models for optimal formulation selection
Combination approaches — Synergistic multi-strain/multi-species formulations
Functional validation — Metabolomics to confirm mechanism

References

[Scheperjans, F., et al, (2015) (2015)](https://doi.org/10.1002/mds.26069)

[Keshavarzian, A., et al, (2015) (2015)](https://doi.org/10.1002/mds.26316)

[Unknown, Hamady, M., & Knight, R. (2009). Microbial community profiling for human microbiome projects: Tools, techniques, and challenges (2009)](https://doi.org/10.1101/gr.085464.108)

[Quince, C., et al, (2017) (2017)](https://doi.org/10.1038/nbt.3935)

[Barone, M., et al, (2020) (2020)](https://doi.org/10.1007/s00702-020-02225-8)

[Houser, M. C., et al., (2022). Stool microbial communities in movement disorders (2022)](https://doi.org/10.1016/j.parkreldis.2022.06.007)

[Depommier, C., et al, (2019) (2019)](https://doi.org/10.1080/19490976.2019.1592421)

📖 View canonical wiki page →